Abstract 399P
Background
LX-039 is an oral SERD that blocks ER signaling pathway through receptor antagonism and degradation. LX-039 demonstrated robust antitumor efficacy and good PK profile in preclinical studies.
Methods
This was a multi-center, open-label, first in human, dose escalation and expansion phase I study to evaluate the safety, efficacy and PK/PD profiles of LX-039 monotherapy in postmenopausal patients(pts) with histologically confirmed ER+, HER2- ABC, who had failed ≥1 line endocrine therapy and ≤2 line chemotherapy. The initial dose was 50 mg, sequentially escalated from 100 mg to 1200 mg via traditional "3+3” design. LX-039 was administrated once daily in 28-day cycles until unacceptable toxicity, progression, or withdrawal of consent. 18FES PET/CT scan was undergone on baseline and day 28 after treatment. Primary endpoint was MTD, secondary endpoints included safety, efficacy, and PK/PD.
Results
44 pts (median age 56.5, ECOG = 1: 88.6%, visceral metastasis: 77.3%) were enrolled. All pts received prior endocrine therapy (range: 1-7 lines, 56.8% fulvestrant) and/or CDK4.6i(40.9%), chemotherapy(54.5%) in the advanced setting. Two pts experienced DLTs: G3 hepatic function abnormal in 1000 mg cohort (1/6) and G4 ALT increased in 1200 mg cohort (1/1), so MTD was not reached. TRAEs were mostly grade 1-2 and experienced by ≥20% of pts were diarrhea (81.8%, G3 15.9%), ALT increased (56.8%, ≥G3 15.9%); AST increased (47.7%, G3 4.5%), fatigue (38.6%), decreased appetite (29.5%), vomiting (29.5%), nausea (27.3%), weight decreased (22.7%). Dose-dependent plasma exposure was seen with an estimated half-life of approximately 7 h. In 29 pts with measurable lesions who received 600 mg or higher doses, 4 pts (13.8%) achieved partial response, with median DOR of 7.4 months. Median PFS in the ITT population was 5.5months (95% CI: 3.5, 5.9). CBR at 24 weeks was 40.0% and DCR was 70.3%. 18FES-PET scan (n = 13) showed that all patients experienced SUVmax decrease from baseline with a median reduction of > 70 %.
Conclusions
LX-039 was well tolerated with preliminary anti-tumor activity in ER+, HER2- ABC. RP2D was determined at 600 mg QD and a phase II trial is being planned.
Clinical trial identification
NCT04097756.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Luoxin pharmaceutical.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
358P - Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Presenter: Savannah Roy
Session: Poster session 03